BRIEF-Belite Bio Announces Positive Topline Results From Pivotal Global, Phase 3 Dragon Trial Of Tinlarebant
Reuters
Dec 01
BRIEF-Belite Bio Announces Positive Topline Results From Pivotal Global, Phase 3 Dragon Trial Of Tinlarebant
Dec 1 (Reuters) - Belite Bio Inc BLTE.O:
NEW HOPE FOR PEOPLE LIVING WITH A DISEASE ONCE DEEMED UNTREATABLE: BELITE BIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PIVOTAL GLOBAL, PHASE 3 DRAGON TRIAL OF TINLAREBANT IN ADOLESCENTS WITH STARGARDT DISEASE
BELITE BIO INC - TO FILE NDA WITH FDA IN 1H 2026
BELITE BIO INC: TINLAREBANT MET PRIMARY EFFICACY ENDPOINT IN A GLOBAL PHASE 3 TRIAL
BELITE BIO INC: TINLAREBANT WAS WELL TOLERATED THROUGHOUT TRIAL
Source text: ID:nGNX7FD3q4
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.